Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
Table 1
A list of currently approved cancer immunotherapies.
FDA/EMA
MHLW (Japan)
Nivolumab (Anti-PD-1 Ab)
Melanoma
Melanoma
non-small cell lung cancer
non-small cell lung cancer
renal cell carcinoma
renal cell carcinoma
Hodgkin's lymphoma
Hodgkin's lymphoma
Head neck cancer
Head neck cancer
MSI-H/dMMR colorectal cancer
gastric cancer
hepatocellular carcinoma
diffuse malignant pleural mesothelioma
small cell lung cancer
Esophageal cancer
MSI-high colorectal cancer
Pembrolizumab (Anti-PD-1 Ab)
Melanoma
Melanoma
non-small cell lung cancer
non-small cell lung cancer
Head neck cancer
Urothelial cancer
Hodgkin's lymphoma
MSI-high solid tumor
Urothelial cancer
renal cell carcinoma (combination)
MSI-high colorectal cancer
Head neck cancer (mono/combination)
MSI-high cancer
gastric cancer
cervical cancer
hepatocellular carcinoma
Merkel cell carcinoma
renal cell carcinoma
endometrial cancer
Avelmab (Anti-PD-L1 Ab)
Merkel cell carcinoma
Merkel cell carcinoma
renal cell carcinoma
renal cell carcinoma (combination)
Urothelial cancer
Atezolizumab (Anti-PD-L1 Ab)
Urothelial cancer
non-small cell lung cancer
non-small cell lung cancer
extensive-disease small cell lung cancer.
breast cencer
triple negative breast cancer
small cell lung cancer
Durvalumab (Anti-PD-L1 Ab)
Urothelial cancer
non-small cell lung cancer (stage 3)
non-small cell lung cancer
Ipilimumab (Anti-CTLA4 Ab)
Melanoma
Melanoma (mono/combination)
renal cell carcinoma
renal cell carcinoma (combination)
MSI-H/dMMR colorectal cancer
Kymriah (CAR-T)
B-ALL (<25 yars-old)
B-ALL (<25 yars-old)
DLBCL (Hodgkin's lymphoma)
Yescarta (CAR-T)
DLBCL (Hodgkin's lymphoma)
not approved
Sipuleucel-T (Provenge) (DC-vaccine)
Prostate cancer
not approved
Combination with axitinib, monotherapy or combination with chemotherapy, monotherapy or combination with nivolumab, combination with nivolumab. MSI-H/dMMR: microsatellite instability-high/deficient mismatch repair; B-ALL: B cell acute lymphoblastic leukemia; DLBCL: diffuse large B cell lymphoma; Ab: antibody; PD-1: programmed death-1; PD-L1: programmed death ligand-1; CAR: chimeric antigen receptor; DC: dendritic cell; FDA: Food and Drug Administration; EMA: European Medicines Agency; MHLW: Ministry of Health, Labour and Welfare.